TITLE

Prognosis and Therapy When Acute Promyelocytic Leukemia and Other "Good Risk" Acute Myeloid Leukemias Occur as a Therapy-Related Myeloid Neoplasm

AUTHOR(S)
Larson, Richard A.; Le Beau, Michelle M.
PUB. DATE
August 2011
SOURCE
Mediterranean Journal of Hematology & Infectious Diseases;2011, Vol. 3 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Treatment for a pre-existing condition using chemotherapy, radiation therapy, immunosuppressive therapy, or a combination of these modalities may lead to the devastating complication of therapy-related myelodysplastic syndrome or acute myeloid leukemia (t-MDS/t-AML), collectively known as therapy-related myeloid neoplasm (t-MN). This disorder arises as a direct consequence of mutational events induced by the primary treatment. The outcomes for these patients have been historically poor compared to people who develop AML de novo. Currently comprising 10-20% of all cases of AML, t-MN is relatively resistant to conventional leukemia therapies, and is associated with short survival times. Median life expectancy from diagnosis is about 8-10 months in most series. Although the spectrum of cytogenetic abnormalities in t-AML is similar to AML de novo, the frequency of unfavorable cytogenetics, such as a complex karyotype or deletion or loss of chromosomes 5 and/or 7, is considerably higher in t-MN. Two distinct groups of patients with t-MN have been described. The more common subtype, seen in about 75% of patients, typically occurs 5-7 years after first exposure to alkylating agents or radiation, is often preceded by a myelodysplastic syndrome (MDS), and is frequently accompanied by clonal cytogenetic abnormalities such as the loss of all or part of chromosomes 5 or 7. Mutations of the P53 tumor suppressor gene are also common. The risk is related to total cumulative exposure over time to alkylating agents. In contrast, among individuals who develop t-AML after treatment with topoisomerase II inhibitors, the latency period to the development of t-AML is often only 1-3 years, antecedent MDS is rare, and gene rearrangements involving MLL at 11q23 or RUNX1/AML1 at 21q22 are common. It is now well recognized that APL and other subtypes of AML with balanced translocations sometimes occur as therapy-related myeloid neoplasms (t-MN) in patients who have previously received cytotoxic therapy or ionizing radiation therapy (RT). The most of this review will focus on these "good risk" leukemias, i.e. those with APL or inv(16)/t(16;16) or t(8;21).
ACCESSION #
85762132

 

Related Articles

  • In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Hackanson, Björn; Robbel, Christian; Wijermans, Pierre; Lübbert, Michael // Annals of Hematology;Dec2005 Supplement, Vol. 84, p32 

    Low-dose demethylating agents such as 5-aza-2′-deoxycytidine (decitabine, DAC) and 5-azacytidine (azacitidine, Vidaza) have been explored for the treatment of myelodysplasia, acute myeloid leukemia, and hemoglobinopathies since the early 1980s, aiming to revert a methylator phenotype....

  • Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Lancet, J. E.; List, A. F.; Moscinski, L. C. // Leukemia (08876924);Mar2007, Vol. 21 Issue 3, p586 

    The article describes the case of a 55-year-old woman who was diagnosed with chromosome 5q deletion acute myeloid leukemia and who achieved complete remission with lenalidomide treatment. Lenalidomide is an immunomodulatory drug that yields erythroid, pathologic and cytogenetic response in...

  • Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine. Dalley, Christopher D; Lillington, Deborah L; Bradburn, Michael; Carter, Maxine; Amess, John A; Rohatiner, Ama Z S; Lister, T Andrew // Hematology Journal;2002, Vol. 3 Issue 5, p237 

    Elderly patients (age > 60 years) with AML who are selected for curative treatment frequently receive anthracycline/cytarabine containing regimens. The anthracendione mitoxantrone (MTN) in combination with cytarabine (Ara-C) produces comparable complete remission rates to other regimens and may...

  • High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR. Majhail, N. S.; Bajorunaite, R.; Lazarus, H. M.; Wang, Z.; Klein, J. P.; Zhang, M. J.; Rizzo, J. D. // Bone Marrow Transplantation;Mar2011, Vol. 46 Issue 3, p385 

    We describe the long-term outcomes of autologous hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All patients were in continuous CR for 2 years after HCT. Patients were predominantly transplanted in CR1 (78%) and had good or...

  • European Society of Hematology.  // BioWorld Today;6/9/2009, Vol. 20 Issue 109, p6 

    The article reports on the data from Celgene International S&aagrave;rl which demonstrated that Vidaza treatment significantly extended overall survival and helped patients with myelodysplastic syndromes (MDS) become or remain independent from red blood cell transfusion. Patients who benefited...

  • DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AML. Müller, Claudia I.; Rüter, Björn; Koeffler, H. Phillip; Lübbert, Michael // Current Pharmaceutical Biotechnology;Oct2006, Vol. 7 Issue 5, p315 

    Differential methylation of CpG islands is a regulatory mechanism for promoter activity of different classes of genes, including tissue-specific genes. These CpG islands are targets for transformation-associated, aberrant hypermethylation activity during leukemogenesis. Therefore the...

  • Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Garcia-Manero, G.; Kantarjian, H.M.; Kornblau, S.; Estey, E. // Leukemia (08876924);Sep2002, Vol. 16 Issue 9, p1888 

    Focuses on treatment-related myelodysplastic syndrome or acute myelogenous leukemia in acute promyelocytic leukemia patients. Median disease-free survival; Post-remission therapy; Cytogenetic analysis.

  • Primary graft failure following unrelated cord blood transplantation with high-dose of CD34+ cells in the treatment of AML/MDS. Lu Xiaoxi; Wan Zhi; Ma Zhigui; Gao Ju; Zhu Yiping // Organ Transplantation / Qi Guan Yi Zhi;Nov2014, Vol. 5 Issue 6, p343 

    Objective To analysis the cause of primary graft failure of unrelated cord blood transplantation with high-dose of CD34 + cells in treatment of acute myelocytic leukemia (AML) /myelodysplastic syndrome (MDS).Methods A 4-year-old girl was diagnosed AML/MDS at the Department of Pediatric...

  • Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy. Shahjahani, Mohammad; Khodadi, Elahe; Seghatoleslami, Mohammad; Asl, Javad Mohammadi; Golchin, Neda; Zaieri, Zeynab Deris; Saki, Najmaldin // Oncology Reviews;2015, Vol. 9 Issue 1, p7 

    Acute myeloid leukemia (AML) is the most common acute leukemia in adults, which is heterogeneous in terms of morphological, cytogenetic and clinical features. Cytogenetic abnormalities, including karyotype aberrations, gene mutations and gene expression abnormalities are the most important...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics